Kymera Therapeutics soars as Sanofi expands phase 2 trials - Kymera Therapeutics Inc , (NASDAQ:KYMR) a clinical-stage biopharmaceutical firm specializing in the development of novel small molecule medicines using targeted protein degradation (TPD), surged 23.7% on Tuesday following a significant announcement.

After an Independent Data Review Committee examined the preliminary safety and efficacy data of KT-474, pharmaceutical giant Sanofi (EPA:SASY) has indicated its intention to expand the ongoing Phase 2 trials for Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This move is expected to expedite the progression towards pivotal studies.

Nello Mainolfi, PhD, Founder, President, and CEO of Kymera Therapeutics, expressed enthusiasm, noting, “This expansion, supported by the results of the interim analysis, is intended to accelerate overall timelines and inform future registrational trials. We look forward to sharing further information as it is available, including trial designs and updated timing for the expanded Phase 2 data readouts.”

⚠️Stay up to date with the latest company news using InvestingPro! Our Summer Sale is now on, click here to save over 50%!⚠️

Analysts from Truist and Stifel also responded positively to the news. Truist analysts stated that the Phase 2 HS/AD expansion of KT-474 after the interim analysis bodes well for the program, reiterating a 'Buy' stance.

Meanwhile, Stifel analysts suggested that the update strongly indicates that KT-474 has demonstrated an efficacy signal with clean early safety in more than one disease. This should enhance the value for this asset and Kymera's co-co opt-in.

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68.5% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: